We demonstrated that PARK2 may be a bona fide tumor suppressor gene that may be responsible for the development of progression lung cancer with COPD, suggesting PARK2 as a potential target to reduce the risk of COPD and lung cancer. This evidence concerns the gene ENSG00000279284 and lung carcinoma.